Syncope is sudden transient loss of consciousness followed by spontaneous complete recovery; it is a very common problem and can be a precursor to sudden death. This study will increase the early identification of patients with serious underlying arrhythmia by combining our Canadian Syncope Arrhythmia Risk Score (CSARS) with innovative remote (out-of-hospital) monitoring technology. Approximately 2-3% of ED syncope patients will suffer arrhythmia or die from unknown cause within 30-days of ED disposition (in-patient or outside the hospital). It is the concern for occult arrhythmia and its associated mortality that leads to prolonged cardiac monitoring in the ED, observation units or by hospitalization; and wide variations in investigations and hospitalization. New and innovative technology has made remote monitoring feasible for prolonged periods (15-30 days), and is reliable. This technology allows arrhythmias to be transmitted live to a central monitoring station automatically based on the device algorithm or by the touch of a button when patients are symptomatic. However, lack of tools to identify those at risk has limited the use of this new technology to improve patient outcomes. The CSARS tool, developed to predict the 30-day risk of arrhythmia/death showed that higher-risk (score ≥3) patients have a 17.2% observed risk arrhythmia/death within 15 days. The aim of this randomized controlled trial (RCT) is to compare the diagnostic yield of 15-day event monitor to 48-hour holter monitor (usual care) among higher-risk syncope patients discharged home at 10 Canadian EDs.